[{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asymchem Laboratories \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Asymchem Laboratories \/ First Wave BioPharma"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AUM601","moa":"TRKA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asymchem Laboratories \/ Asymchem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Asymchem Laboratories \/ Asymchem Laboratories"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asymchem Laboratories \/ LaNova Medicines","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem Laboratories \/ LaNova Medicines"}]

Find Clinical Drug Pipeline Developments & Deals by Asymchem Laboratories

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for t...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 01, 2022

                          Lead Product(s) : AUM601

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : AUM Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The partnership between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 16, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : LaNova Medicines

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the terms of the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          October 11, 2020

                          Lead Product(s) : Yeast Recombinant Lipase,Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : First Wave BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank